The relationship between metabolic syndrome score and cardiac ischemia detected by noninvasive cardiac tests

Noninvasive cardiac tests performed in patients with high metabolic risk scores showed more ischemia. Metabolic risk score should be considered in the evaluation of patients for coronary artery disease.

Keywords: Metabolic risk score, non-invasive tests, ischemia

ÖZET

Amaç: Kardiyovasküler hastalıklar halen önde gelen mortalite ve morbidite nedenidir. İnvaziv olmayan kardiyak testler klinik uygulamada semptomatik hastalarda CAD tanısı için kullanılmaktadır. Metabolik sendrom (MS), koroner arter hastalığı (CAD) için iyi bilinen bir risk faktörüdür. Bu çalışmada metabolik sendrom skoru ile invaziv olmayan kardiyak testlerin sonuçları arasındaki ilişiği araştırmayı amaçladık.
Yöntem: Göğüs ağrısı ile kardiyoloji bölümüne başvuran toplam 329 hasta çalışmaya dahil edildi. Her bir hasta için sıfır ile beş arasında değişen Ulusal Kolesterol Eğitim Programı (NCEP) Yetiştirin Tedavisi Panel III (ATP III) kriterlerine dayalı metabolik sendrom (MS) puanı hesaplandı. Fizik muayene ve rutin laboratuvar testlerinden sonra ön test olasılığı yüksek olan hastalara, göğüs ağrısını kardiyak olmayan nedenlerden dışlamak için invaziv olmayan kardiyak testler (koşu bandı testi ve miyokard perfüzyon sintigrafisi) yapıldı. Invaziv olmayan testlerin sonuçları hastaların metabolik risk skoru ile değerlendirildi.

Bulgular: Çalışma popülasyonu 192 (% 58.4) erkek ve 137 (% 41.6) kadın denekten oluştu. Ortalama yaş iskemisi olmayan hastalarda 68.3 ± 9 ve iskemisi olan hastalarda 69.4 ± 7.2 (p = N/S) idi. İskemisi olmayan hastalarda metabolik skor 1.8 ± 1.1 idi. İskemili hastalarda 2.67 ± 1.3 idi (p = <0.01) Koroner iskemili hastalarda iskemisi olmayan hastalardan daha yüksek metabolik sendrom skoru vardı (p <0.01).

Sonuç: Bu çalışmada, yüksek metabolik risk skoru olan hastalarda yapılan invaziv olmayan kardiyak testler daha fazla iskemi göstermiştir. Koroner arter hastalığı olan hastaların değerlendirilmesinde metabolik risk skoru dikkate alınmalıdır.

Anahtar sözcükler: Metabolik sendrom risk skoru, girişimsel olmayan kardiyak testler, iskemi

INTRODUCTION
Cardiovascular diseases especially coronary artery diseases still leading cause of death all around the world. Non-invasive functional imaging for myocardial ischemia or coronary CTA is recommended as the initial test for diagnosing CAD in symptomatic patients in whom obstructive CAD cannot be excluded by clinical assessment alone 1. Metabolic syndrome is an important risk factor for type 2 diabetes mellitus and cardiovascular disease 2. Abdominal obesity, high blood pressure, high fasting glucose, high triglycerides and reduced levels of high-density lipoprotein cholesterol (HDL-C) are the component of metabolic syndrome defined by 2001 National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) report 3. The metabolic score is calculated by giving a score to each parameter used in the diagnosis of metabolic syndrome and its relationship with the severity of coronary artery disease has been demonstrated4. The aim of this study was to examine the effect of MS on results of non-invasive cardiac tests for ischemia.

MATERIAL AND METHODS
Study population
The total number of 329 patients who admitted with chest pain to cardiology department were included in the study. Patients who had previous myocardial infarctus in the last 1 month, patients with CAD who previously underwent PCI and CABG or receiving statin before lipid measurement. Patients with high test probability underwent non-invasive test (tread mill test and myocardial perfusion scintigraphy) to explain cause of chest pain. Ruthin biochemistry test detailed physical examination performed. Informed consent was obtained from the subjects before enrolment and the study protocol was approved by the local ethics committee.

Metabolic syndrome score
After detailed anamnesis, physical and laboratory examination, MS scores were determined according to the criteria listed below:

- Waist circumference > 102 cm for males, > 88 cm for females: one point.
- Diagnosed hypertension or receiving antihypertensive or two measurement of blood pressure exceeding 130 ⁄ 85 mmHg: one point.
- Diagnosed diabetes mellitus or receiving antidiabetic treatment or fasting blood glucose > 110 mg ⁄ dl: one point
- High-density lipoprotein cholesterol < 40 mg ⁄ dl for males, < 50 mg ⁄ dl: one point.
- Triglyceride > 150 mg ⁄ dl: one point.

Statistical Methods
Data are demonstrated as mean ± SD for normally distributed continuous variables, median (minimum– maximum) for skew-distributed continuous variables, and frequencies for categorical variables. Pearson chi- squared test was performed for the comparison of categorical variables. Means of normally distributed continuous variables were compared by ANOVA. Skew-distributed continuous variables were compared by Mann–Whitney U-test. Post hoc analysis was performed by Tukey test. Statistical Package for Social Sciences (SPSS) for Windows version 17.0 (SPSS Inc., Chicago, IL) was used for the analysis and p < 0.05 was considered as significant.

RESULTS
The study population consist of 329 patients (137 women 41.6% and 192 men 58.4%). Ischemia were detected in 52 (15.8%) patients. There were no difference between patient regarding to sex and ischemia positive results obtained from noninvasive tests (female n:25 7.6% male n:27
Mean age was 68.3 9.05 year in patients without ischemia and 69.4 ±7.2 year with ischemia. (p: N/S).

There were no significant difference regarding to waist circumference 97.3± 9.5 vs 99.8±9.9 high-density lipoprotein cholesterol level 54.09±15.2 vs 53.6±17.8 between two groups. fasting blood glucose levels were (124.7±44.8 vs 110.7±34.7 p:0.039)high in patients with ischemia There were182 hypertensive patients without ischemia 36 hypertensive patients with ischemia (p: N/S), 77 diagnosed diabetes mellitus patients without ischemia and 24 diagnosed diabetes mellitus patients with ischemia (p:0.08). The metabolic score of patients without ischemia was 1.8±1.1 and 2.6±1.3 patients with ischemia (p:N/S). Table 1

Relative Frequency of Various Markers of the Metabolic Syndrome (MS) in Patients With 0 to 5 Markers were shown in Table 2. Increased blood pressure was the prominent marker in all metabolic scores. In patients with high metabolic risk score (Mets), the rate of detection of ischemia was higher with non-invasive tests (Mets 5 n:6 46.2% vs n:7 53.8%; Mets 4 n:7 41.2% vs n:10 58.8% Mets 3 n:15 20.5% vs n:58 79.5% Mets2 n:13 13.5%vs n:83 86.5% Mets1 n:10 %9.6 vs n:94 mets 0 n:1 3.8% vs n:25 96.2% p<0.001). Figure 1

**DISCUSSION**

This is the first study evaluating MS score and ischemia detection by non-invasive cardiac tests. The present study revealed that as MS score increases, the probability of ischemia detection with non-invasive tests increases.

The first thing that should be done in the patient presenting with chest pain is to distinguish whether the unstable angina pectoris or acute coronary syndrome is present.

After the acute condition is excluded, further evaluation should be made according to the pre-test risks of the patients. After the acute condition is excluded, further evaluation should be made according to the pre-test risks of the patients. Recent guidelines suggest that if the pretest probability is high above15% test results more reliable. If the pretest probability low than 5% the higher likelihood of a false-positive test must be considered. Pre-test probabilities of obstructive coronary artery disease in 15 815 symptomatic patients according to age, sex, and the nature of symptoms in a pooled analysis of contemporary data the presence of risk factors for CVD (such as family history of CVD, dyslipidaemia, diabetes, hypertension, smoking, and other lifestyle factors) that increase the probability of obstructive CAD can be used as modifiers of the PTP estimate. The MS is identified in the presence of 3 of these quantitatively identified markers: elevated waist circumference, high normal or elevated blood pressure, elevated triglycerides and glucose, as well as low HDL cholesterol levels. The MS is likely to evolve gradually. Even the presence of 3 risk markers may increase the risk of CAD, and patients with 4 or 5 risk markers may have more severe risk factors and characteristics of CAD.

In our current study, we found that as the metabolic syndrome risk score increased, the rate of ischemia detection increased with non-invasive tests. In evaluating pretest probability, it may be necessary to consider the metabolic risk score as well as age, gender and symptom.
### Table 1: Basal characteristic properties of the patients

|                      | With ischemia    | Without ischemia | P    |
|----------------------|------------------|------------------|------|
| Age                  | 69.44±7.2        | 68.37±9.05       | N/S  |
| Glucose              | 124.7±44.8       | 110.7±34.7       | 39   |
| Total cholesterol    | 214.5±31.9       | 202±49           | N/S  |
| Triglyceride         | 166.4±88.5       | 143.4±111.7      | N/S  |
| High density lipoprotein | 53.65±17.8   | 54.09±15.2       | N/S  |
| Low density lipoprotein | 127.7±29.8    | 118.8±37.9       | N/S  |
| Very low density lipoprotein | 33.2±17.7   | 28.6±22.3        | N/S  |
| Insulin resistance   | 0.61±0.49        | 0.38±0.48        | N/S  |
| Pulse                | 70.2±9.08        | 70.8±10.01       | N/S  |
| Diastolic blood pressure | 73.2±10.02     | 74.4±10.04       | N/S  |
| Systolic blood pressure | 115.8±14.8     | 119.8±18.2       | N/S  |
| Height               | 164.3±8.6        | 164.9±8.3        | N/S  |
| Weight               | 75.8±13.9        | 73.7±11.7        | N/S  |
| Hip circumferences   | 99.8±9.9         | 97.3±9.5         | N/S  |
| Waist circumferences | 92.1±12.09       | 89.6±10.3        | N/S  |
| Metabolic syndrome score | 2.67±1.3         | 1.83±1.12        | N/S  |

### Table 2: Relative Frequency of Various Markers of the Metabolic Syndrome (MS) in Patients With 0 to 5 Markers

| MS score | n  | Decreased HDL Cholesterol Levels* | Increased Blood Pressure† | Increased Triglyceride Levels‡ | Increased Waist Circumference§ | Increased Glucose Levels ** |
|----------|----|----------------------------------|---------------------------|-------------------------------|-------------------------------|-------------------------------|
| 0        | 26 | 0                                | 0                         | 0                             | 0                             | 0                             |
| 1        | 104| 6 5.8%                           | 61 58.7%                   | 13 12.5%                      | 15 14.4%                      | 8 7.7%                        |
| 2        | 96 | 15 15.6%                         | 70 72.9%                   | 27 28.1%                      | 31 32.3%                      | 44 45.8%                      |
| 3        | 73 | 34 %46.6                         | 57 78.1%                   | 45 61.6%                      | 32 43.8%                      | 39 53.4%                      |
| 4        | 17 | 11 %64.7                         | 17 100%                    | 12 70.6%                      | 12 70.6%                      | 12 %70.6                      |
| 5        | 13 | 13 %100                          | 13 100%                    | 12 100%                       | 13 100%                       | 12 %100                       |

*For men:>1.03 mmol/L or 40 mg/dl; for women:>1.29 mmol/L or 50 mg/dl. †>130/85 mm Hg. ‡>1.69 mmol/L or 150 mg/dl. §For men >102 cm; for women >88 cm. **>6.11 mmol/L or 110 mg/dl.
REFERENCES

1. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J [Internet]. 2020 Jan 14;41(3):407–77.

2. Solymoss BC, Bourassa MG, Lespérance J, Levesque S, Marcil M, Varga S, et al. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coron Artery Dis [Internet]. 2003 May;14(3):207–12.

3. Lipsy RJ. Introduction. J Manag Care Pharm [Internet]. 2003 Jan;9(1 Supp A):2–5.

4. Yavuz B, Kabakci G, Aksoy H, Tulumen E, Deveci OS, Aytemir K, et al. Determining the relationship between metabolic syndrome score and angiographic severity of coronary artery disease. Int J Clin Pract [Internet]. 2008 Feb 7;62(5):717–22.

5. Juarez-Orozco LE, Saraste A, Capodanno D, Prescott E, Ballo H, Bax JJ, et al. Impact of a decreasing pre-test probability on the performance of diagnostic tests for coronary artery disease. Eur Hear J - Cardiovasc Imaging [Internet]. 2019 Apr 14;

6. Foldyna B, Udelson JE, Karády J, Banerji D, Lu MT, Mayrhofer T, et al. Pretest probability for patients with suspected obstructive coronary artery disease: re-evaluating Diamond-Forrester for the contemporary era and clinical implications: insights from the PROMISE trial. Eur Heart J Cardiovasc Imaging [Internet]. 2019 May 1;20(5):574–81.